{Reference Type}: Journal Article
{Title}: Should Antimicrobial Resistance Limit Access to an Organ Transplant?
{Author}: Courtwright A;
{Journal}: AMA J Ethics
{Volume}: 26
{Issue}: 5
{Year}: 2024 May 1
暂无{DOI}: 10.1001/amajethics.2024.367
{Abstract}: Burkholderia cenocepacia (B cenocepacia) is a gram-negative bacteria associated with significant morbidity and mortality following lung transplantation. Most US transplant programs consider B cenocepacia colonization to be an absolute contraindication to transplantation. This article argues that, if clinicians have good clinical reasons to expect poor outcomes for patients with B cenocepacia, then offering transplantation anyway is an abrogation of clinicians' fiduciary duties. This article also discusses other fiduciary obligations transplant programs might have to patients with B cenocepacia, such as referring to another transplant center, considering novel treatment options, and investigating how the infection's virulence factors stratify that patient's risk for poor transplant outcomes.